New hope for advanced cancer? early trial of BC2027 begins

NCT ID NCT07368478

Recruiting now Disease control Sponsor: Biocity Biopharmaceutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug, BC2027, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors or slow their growth. Participants receive BC2027 by IV infusion, and the study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BC2027
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 180 participants, so the drug may not prove safe or effective. Side effects and lack of tumor shrinkage are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer esophageal squamous cell carcinoma hepatocellular carcinoma non-small cell lung carcinoma ovarian clear cell adenocarcinoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCIES

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai, China, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.